{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T19:49:20Z","timestamp":1722196160342},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,3,15]]},"DOI":"10.2169\/internalmedicine.2171-23","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T22:12:42Z","timestamp":1690927962000},"page":"843-846","source":"Crossref","is-referenced-by-count":2,"title":["Silent Thyroiditis Associated with Ropeginterferon \u03b1-2b in a Patient with Polycythemia Vera"],"prefix":"10.2169","volume":"63","author":[{"given":"Keita","family":"Kirito","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126: 1762-1769, 2015.","DOI":"10.1182\/blood-2015-04-637280"},{"key":"2","unstructured":"2. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7: e196-e208, 2020."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol 8: e175-e184, 2021.","DOI":"10.1016\/S2352-3026(20)30373-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Edahiro Y, Ohishi K, Gotoh A, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol 116: 215-227, 2022.","DOI":"10.1007\/s12185-022-03341-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kiladjian JJ, Klade C, Georgiev P, et al.; the PROUD-PV Study Group. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 36: 1408-1411, 2022.","DOI":"10.1038\/s41375-022-01528-x"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 43: 661-672, 2006.","DOI":"10.1002\/hep.21146"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bhattacharya S, Goyal A, Kaur P, Singh R, Kalra S. Anticancer drug-induced thyroid dysfunction. Eur Endocrinol 16: 32-39, 2020.","DOI":"10.17925\/EE.2020.16.1.32"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 23: 703-712, 2009.","DOI":"10.1016\/j.beem.2009.07.004"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol 4: e165-e175, 2017.","DOI":"10.1016\/S2352-3026(17)30030-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mammen JS, Ghazarian SR, Pulkstenis E, Subramanian GM, Rosen A, Ladenson PW. Phenotypes of interferon-\u03b1-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex. J Clin Endocrinol Metab 97: 3270-3276, 2012.","DOI":"10.1210\/jc.2012-1026"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Dalgard O, Bj\u00f8ro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 251: 400-406, 2002.","DOI":"10.1046\/j.1365-2796.2002.00974.x"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Koh LKH, Greenspan FS, Yeo PPB. Interferon-\u03b1 induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7: 891-896, 1997.","DOI":"10.1089\/thy.1997.7.891"},{"key":"13","unstructured":"13. Paulsrud C, Hasselbalch HC, Bjerrum OW. Autoimmune thyroid disease in patients with Philadelphia-negative chronic myeloproliferative neoplasms treated with interferon-alpha. J Blood Res Hematol Dis 1: 4, 2016."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hasham A, Zhang W, Lotay V, et al. Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways. J Autoimmun 44: 61-70, 2013.","DOI":"10.1016\/j.jaut.2013.04.002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Obo\u0142o\u0144czyk \u0141, Siekierska-Hellmann M, Wi\u015bniewski P, et al. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study. Postepy Hig Med Dosw (Online) 71: 842-849, 2017.","DOI":"10.5604\/01.3001.0010.4782"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Marchetti M, Vannucchi AM, Griesshammer M, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9: e301-e311, 2022.","DOI":"10.1016\/S2352-3026(22)00046-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kim SY, Bae SH, Bang SM, et al. The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med 36: 45-62, 2021.","DOI":"10.3904\/kjim.2020.319"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Pastore F, Martocchia A, Stefanelli M, et al. Hepatitis C virus infection and thyroid autoimmune disorders: a model of interactions between the host and the environment. World J Hepatol 8: 83-91, 2016.","DOI":"10.4254\/wjh.v8.i2.83"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/6\/63_2171-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T03:31:40Z","timestamp":1710559900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/6\/63_2171-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2171-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"article-number":"2171-23"}}